SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The PEPE community is heavily debating a potential short squeeze while navigating ongoing market volatility and speculative price predictions. Active discussions on social forums are increasingly blending crypto-market sentiment with polarizing political discourse, drawing mixed reactions from traders.

Shake Shack, Inc. engages in the operation and licensing of Shake Shack restaurants which serve burgers, hot dogs, crinkle cut fries, shakes, frozen custard, beer, wine, and related products. The company was founded by Daniel Harris Meyer on September 23, 2014 and is headquartered in New York, NY.

Shake Shack Inc - Ordinary Shares - Class A

Shake Shack is seeing a surge in investor confidence and insider buying, with the CEO and founder purchasing millions in shares to signal conviction amid recent market volatility. Community members are actively debating the stock's potential for a turnaround based on store expansion, improved operational efficiency, and anticipation of long-term growth versus ongoing concerns regarding margin recovery and consumer discretionary spending.

OpenAI

OpenAI is trending as investors react to a potential delay in the company's highly anticipated IPO amid broader market volatility and questions about long-term profitability. Community discussions remain polarized, focusing on recent legal challenges regarding trade secrets and debate over the sustainability of massive AI infrastructure spending.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is at the center of investor focus as the market closely monitors the impact of surging jet fuel costs and geopolitical uncertainty on its upcoming quarterly results. The community is actively debating the sustainability of the carrier's premium strategy and its ability to maintain profit margins amid industry-wide cost pressures and shifting air travel demand.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee Inc. is trending as investors digest a recent buy rating from Goldman Sachs while speculating on the long-term impact of its share buyback program. Discussion is divided between bullish long-term holders highlighting store expansion and potential future relisting, and frustrated traders venting over persistent OTC price volatility and a lack of clear catalysts.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet Inc. is trending as investors react to its official inclusion in the Dow Jones Industrial Average, a move that is expected to trigger structural buying from index-linked capital. The community is actively debating the stock's potential for a breakout, with many focusing on the company's long-term dominance in search, cloud growth, and AI integration as key drivers for a move toward previous highs.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing heightened investor attention as the community anticipates potential regulatory developments and the launch of new platform features, though sentiment remains divided due to ongoing concerns about token dilution and price performance. Meanwhile, the native meme coin MERY.X is trending alongside CRO, with supporters highlighting its decentralized 'rug-proof' structure and strong correlation with the broader Cronos ecosystem as primary catalysts for interest.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending as investors weigh strong clinical data against the impact of a recent $50 million convertible note offering ahead of the July 17 PDUFA date. The community is focused on the binary risk of the upcoming FDA decision on gedatolisib, with many interpreting the institutional capital raise as a sign of long-term confidence despite short-term volatility.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors digest its recent addition to the Dow Jones Industrial Average and ongoing market debate regarding its massive capital expenditure on AI infrastructure versus long-term ROI. The community is actively discussing the stock's valuation gap relative to other tech giants and debating the sustainability of high-level AI spending against the backdrop of potential macroeconomic shifts.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigen (PGEN) is trending as investors debate the potential for institutional accumulation and a short squeeze against a backdrop of volatile price action. The community is focused on recent commercial milestones for the RRP treatment Papzimeos, while some express frustration over aggressive short selling and market manipulation around key price levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?

CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER, Colo., July 1, 2026 BOULDER, Colo., July 1, 2026 /PRNewswire/ --Edgewise Therapeutics, Inc...

Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data

Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data...

Edgewise Therapeutics Reports Improvements In Heart Drug Trial

Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart function improvements.read more...

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Multiple clinical-stage companies are delivered meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events. $NTHI, $SLBT, $CRVO, $EWTX

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive...

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER, Colo., June 3, 2026 BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...

Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal

EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.

EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business

Equity

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones.

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Edgewise Therapeutics Inc

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$45.41
Prev Close	$48.35
Open	$48.09
Dividend Yield	0.00%
50-Day Moving Average	$36.34
Beta	1.40
Avg. Volume	1.96M
PE Ratio	-27.34

52-Week High	$48.40
52-Week Low	$12.30
Market Capitalization	$5.2B
EPS (Annual)	-$1.63
Price to Book	9.90
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

EWTXEdgewise Therapeutics Inc

Latest EWTX News